Oppenheimer Equities Analysts Boost Earnings Estimates for Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOXGet Rating) – Research analysts at Oppenheimer lifted their Q2 2022 earnings estimates for shares of Eloxx Pharmaceuticals in a research report issued on Tuesday, May 10th. Oppenheimer analyst H. Singh now anticipates that the company will earn ($0.12) per share for the quarter, up from their previous estimate of ($0.14). Oppenheimer also issued estimates for Eloxx Pharmaceuticals’ Q3 2022 earnings at ($0.12) EPS, Q4 2022 earnings at ($0.10) EPS, FY2022 earnings at ($0.47) EPS, FY2023 earnings at ($0.46) EPS, FY2024 earnings at ($0.47) EPS, FY2025 earnings at ($0.58) EPS and FY2026 earnings at $0.81 EPS.

Several other research firms also recently commented on ELOX. Zacks Investment Research downgraded Eloxx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 5th. HC Wainwright cut their price objective on Eloxx Pharmaceuticals to $1.00 in a research report on Monday. Finally, B. Riley cut their price objective on Eloxx Pharmaceuticals from $5.00 to $3.00 in a research report on Monday, January 24th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $2.64.

ELOX opened at $0.26 on Friday. The stock’s 50 day moving average price is $0.43 and its two-hundred day moving average price is $0.63. The company has a quick ratio of 4.37, a current ratio of 2.20 and a debt-to-equity ratio of 1.04. Eloxx Pharmaceuticals has a 12-month low of $0.21 and a 12-month high of $2.53.

Eloxx Pharmaceuticals (NASDAQ:ELOXGet Rating) last issued its earnings results on Thursday, March 31st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02).

Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN lifted its holdings in shares of Eloxx Pharmaceuticals by 63.8% during the 2nd quarter. Wells Fargo & Company MN now owns 21,455 shares of the company’s stock valued at $43,000 after purchasing an additional 8,357 shares in the last quarter. Sawtooth Solutions LLC acquired a new stake in Eloxx Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Morgan Stanley raised its position in Eloxx Pharmaceuticals by 1,074.2% in the 2nd quarter. Morgan Stanley now owns 20,161 shares of the company’s stock valued at $39,000 after buying an additional 18,444 shares during the last quarter. Geode Capital Management LLC raised its position in Eloxx Pharmaceuticals by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 798,058 shares of the company’s stock valued at $558,000 after buying an additional 25,222 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Eloxx Pharmaceuticals in the 3rd quarter valued at approximately $45,000. Hedge funds and other institutional investors own 28.25% of the company’s stock.

Eloxx Pharmaceuticals Company Profile (Get Rating)

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.

See Also

Earnings History and Estimates for Eloxx Pharmaceuticals (NASDAQ:ELOX)

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.